Search Results
Investigational Gene Therapy (SRP-9001) Shows Promise in Duchenne Muscular Dystrophy Patients
Webinar: SRP-9001 Data Update from Studies 101, 102, and 103 (August 2022)
Sarepta's SRP-9001 Gene Therapy for Duchenne Muscular Dystrophy Faces FDA Advisory Committee Review
Sarepta's SRP-9001, Gene Therapy, for Duchenne Muscular Dystrophy Faces FDA Decision Delay
In the Pipeline: Restoring Dystrophin - Sarepta Therapeutics (RNA Targeted Therapies)
CureDuchenne and REGENXBIO Webinar: RGX-202 - REGENXBIO’s investigational gene therapy for DMD
In the Pipeline: Gene Therapy - Day 3 - PPMD Annual 2020
MHAD 2021– Dr. Melissa Spencer. USACRISPR/Cas9 gene editing for Duchenne muscular dystrophy
Duchenne Research Pipeline Explained
2022 FUTURES Gene Therapy and Gene Editing Symposium Brunch
In the Pipeline: Gene Therapy (PPMD's 2021 Virtual Annual Conference)
In the Pipeline: Pre-Clinical Gene Therapy (PPMD's 2021 Virtual Annual Conference)
